Fundraising Fox
Akan Biosciences
1 known investors
Find your way into Akan Biosciences
Sign up to find every way you can get introduced to Akan Biosciences
- Your email: who you already know at Akan Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Akan Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
AKAN Biosciences is a biotechnology and cellular therapy company developing injectable, adipose stem cell-based regenerative products to treat degenerative diseases and injuries. Its lead product, StroMel, is in Phase 2 clinical trials for knee osteoarthritis, with additional trials planned for other joints, wound healing, Crohn's disease, sports injuries, and autism.
Investors · 1
Related companies · 9
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Akebia TherapeuticsAkebia Therapeutics develops FDA-approved drug therapies for the treatment of kidney disease. The company is a fully integrated biopharmaceutical organization with a nephrology-focused commercial team and development capabilities.
AskBioAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
ArchonArchon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Ark BiosciencesArk Biosciences is a biopharmaceutical company developing small molecule drugs for infectious diseases, respiratory conditions, neuropsychiatric disorders, and rare diseases. The company has multiple drug candidates in clinical development, with products licensed from partners including Roche and others.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
KenaitxKenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
Companies working in the same space as Akan Biosciences.
Frequently asked questions
- What does Akan Biosciences do?
- AKAN Biosciences is a biotechnology and cellular therapy company developing injectable, adipose stem cell-based regenerative products to treat degenerative diseases and injuries. Its lead product, StroMel, is in Phase 2 clinical trials for knee osteoarthritis, with additional trials planned for other joints, wound healing, Crohn's disease, sports injuries, and autism.
- Who are Akan Biosciences's investors?
- Akan Biosciences's investors include 2Flo Ventures.